<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03873857</url>
  </required_header>
  <id_info>
    <org_study_id>P19-569</org_study_id>
    <nct_id>NCT03873857</nct_id>
  </id_info>
  <brief_title>A Study to Assess Effectiveness of Venclexta (Venetoclax) in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia in Routine Clinical Practice in Russian Federation</brief_title>
  <official_title>Prospective Multi-Center Observational Study to Assess Effectiveness of Venclexta (Venetoclax) in Population of Relapse or Refractory Chronic Lymphocytic Leukemia Patients in Routine Clinical Practice in Russian Federation (FORTE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to assess the effectiveness and safety of venetoclax in patients with
      relapsed and refractory chronic lymphocytic leukemia (CLL) in a real-world setting across
      clinical practice in the Russian Federation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2019</start_date>
  <completion_date type="Anticipated">December 3, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 3, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) 12 Months after Treatment Initiation</measure>
    <time_frame>Up to approximately 12 months after treatment initiation</time_frame>
    <description>ORR is defined as the percentage of participants who reach either complete remission (CR), CR with incomplete bone marrow recovery (CRi), nodular partial remission (nPR), or partial remission (PR) to treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) 24 Months after Treatment Initiation</measure>
    <time_frame>Up to approximately 24 months after treatment initiation</time_frame>
    <description>ORR is defined as the percentage of participants who reach either complete remission (CR), CR with incomplete bone marrow recovery (CRi), nodular partial remission (nPR), or partial remission (PR) to treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Response to Treatment</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>The time to response to treatment is defined by the time between the date of the first venetoclax intake and the date of the first assessment having documented a response (CR, CRi, nPR, and PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Best Response to Treatment</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>The time to best response to treatment is defined by the time between the date of the first venetoclax intake and the date of the best response documented (CR, CRi, nPR, and PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>DoR defined as the number of days from the date of first response (CR, CRi, nPR, or PR) to the date of disease progression or death from any cause, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Next Treatment</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>The time to next treatment is defined as the time between the date of the first venetoclax intake and the date of the first next treatment intake after venetoclax discontinuation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients with Undetectable Minimal Residual Disease (MRD)</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>Patients will be defined as having a clinical remission in the absence of MRD when they have blood or marrow with less than one CLL cell per 10000 leucocytes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) Rate</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>OS is defined as number of days from the date of first dose to the date of the observational period end or death for all dosed patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>Progression-free survival is defined as the interval between the first treatment day to the first sign of disease progression or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in RAND Short Form (SF)-36 Questionnaire</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>Patient quality of life was measured by the RAND-36 health-related quality of life (HRQoL) survey instrument. This questionnaire is comprised of 36 items that assess eight health concepts: physical functioning, role limitations caused by physical health problems, role limitations caused by emotional problems, social functioning, emotional well-being, energy/fatigue, pain, and general health perceptions.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chronic Lymphocytic Leukemia (CLL)</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Venetoclax</arm_group_label>
    <description>Participants in this observational study will receive treatment with venetoclax for up to 24 months for treatment of relapsed or refractory CLL.
The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice and label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>tablet;oral</description>
    <arm_group_label>Venetoclax</arm_group_label>
    <other_name>Venclexta</other_name>
    <other_name>ABT-199</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with relapsed or refractory CLL in a real-world clinical practice setting.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has a confirmed diagnosis of relapsed or refractory CLL.

          -  Patient for whom the physician has decided to initiate CLL treatment with venetoclax
             (mono and combo therapy), or up to 4 weeks after venetoclax treatment initiation

          -  Patient voluntarily agrees to participate in this study and signs informed consent
             form

        Exclusion Criteria:

          -  Has contraindications to venetoclax as listed on the approved local label in Russian
             Federation.

          -  Has Richter syndrome

          -  Participated in a clinical trial with an investigative drug for CLL within 30 days
             prior to treatment initiation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olesya Magdych</last_name>
    <phone>+7 495 258 4277</phone>
    <email>olesya.magdych@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Moscow State budget healthcare institution City Clinical Hospital n.a. Botkin /ID# 212875</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>125284</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Volgograd Regional Clinical Oncology Dispensary /ID# 212366</name>
      <address>
        <city>Volgograd</city>
        <state>Volgogradskaya Oblast</state>
        <zip>400138</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>KGBUZ Regional Clinical Hospital â„– 1 named. Professor S.I. Sergeev /ID# 212367</name>
      <address>
        <city>Khabarovsk</city>
        <zip>680009</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BUZ of the Oryol region &quot;Polyclinic â„– 2&quot; /ID# 214778</name>
      <address>
        <city>Oryol</city>
        <zip>302040</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>State Budgetary Health Institution &quot;Clinical Medical Sanitary Unit No. 1&quot; /ID# 212364</name>
      <address>
        <city>Perm</city>
        <zip>614077</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Russian Research Institute of Hematology and Transfusiology /ID# 212372</name>
      <address>
        <city>Sankt-Peterburg</city>
        <zip>191024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Petersburg state medical University. Acad. I.P. Pavlova /ID# 212368</name>
      <address>
        <city>Sankt-Peterburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>FGBU &quot;NMIC them. V.A. Almazov &quot;of the Ministry of Health of the Russian Federati /ID# 212365</name>
      <address>
        <city>Sankt-Peterburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Komi Republican Oncologic Dispensary /ID# 212370</name>
      <address>
        <city>Syktyvkar</city>
        <zip>167904</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>GBUZ City Clinical Hospital â„– 5 /ID# 212369</name>
      <address>
        <city>Vladimir</city>
        <zip>600031</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BUZ IN &quot;Vologda Regional Clinical Hospital&quot; /ID# 212471</name>
      <address>
        <city>Vologda</city>
        <zip>160002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>GAU of the Republic of Sakha (Yakutia) &quot;Republican hospital â„–1-national center o /ID# 212371</name>
      <address>
        <city>Yakutsk</city>
        <zip>677000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sverdlovsk Regional Clinical Hospital â„–1 /ID# 214777</name>
      <address>
        <city>Yekaterinburg</city>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Central City Hospital â„–7 /ID# 212373</name>
      <address>
        <city>Yekaterinburg</city>
        <zip>620137</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>http://www.rxabbvie.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>March 12, 2019</study_first_submitted>
  <study_first_submitted_qc>March 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2019</study_first_posted>
  <last_update_submitted>September 17, 2019</last_update_submitted>
  <last_update_submitted_qc>September 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Lymphocytic Leukemia (CLL)</keyword>
  <keyword>Cancer</keyword>
  <keyword>Observational Study</keyword>
  <keyword>Venetoclax</keyword>
  <keyword>Relapsed Chronic Lymphocytic Leukemia</keyword>
  <keyword>Refractory Chronic Lymphocytic Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

